Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy
| Autor: | Bateer, Han, Zhanlin, Guo, Ying, Ma, Shirong, Kang, Yufei, Wang, Qiyou, Wei, Xu, Wu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Lung Neoplasms Time Factors Adenocarcinoma of Lung Kaplan-Meier Estimate Adenocarcinoma Gene Frequency Risk Factors Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Odds Ratio Humans Genetic Predisposition to Disease Prospective Studies neoplasms Aged Proportional Hazards Models Chi-Square Distribution Polymorphism Genetic Middle Aged Protective Factors DNA-Binding Proteins Logistic Models Phenotype Treatment Outcome X-ray Repair Cross Complementing Protein 1 Glutathione S-Transferase pi Multivariate Analysis Carcinoma Squamous Cell Female Original Article Cisplatin |
| Zdroj: | International journal of clinical and experimental pathology. 8(4) |
| ISSN: | 1936-2625 |
| Popis: | We investigated the association between the clinical outcome and GSTP1 and XRCC1 gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. We prospectively recruited 325 NSCLC patients between January 2010 and January 2014. Genotypes of GSTP1 A313G, XRCC1 Arg194Trp, Arg280His and Arg399Gln were conducted using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. AG and GG genotypes of GSTP1 A313G were correlated with a higher CR + PR when compared with AA genotype. Furthermore, GA and AA genotypes of XRCC1 Arg399Gln were associated with more CR + PR when compared with GG genotype. In the Cox proportional hazards model, GG genotype of GSTP1 A313G was significantly correlated with a longer median survival time when compared with AA genotype, and it is associated with a heavy decreased risk of death from NSCLC. Moreover, GA and AA genotypes of XRCC1 Arg399Gln had a significantly longer median survival time, and GA and AA genotypes were significantly associated with a moderate reduced risk of death from NSCLC. GSTP1 A313G and XRCC1 Arg399Gln gene polymorphisms might influence the response to cisplatin-based chemotherapy and affect the clinical outcome of advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|